Skip to main content
. 2022 May 12;13:880093. doi: 10.3389/fgene.2022.880093

FIGURE 2.

FIGURE 2

Prognostic performance of MSCNN. The distribution of CT signature of MSCNN and its corresponding recurrence status in the development cohort (A) and validation cohort (C). Kaplan-Meier curves showed a significant survival difference between the high and low risk groups in the development cohort (B) and validation cohort (D). Prognostic analysis of CRC patients in stage II and III subgroups (E–H). Univariable and multivariable analysis of clinical factors in the development cohort (I) and validation cohort (J).